Cazzaniga, G., De Lorenzo, P., Alten, J., Röttgers, S., Hancock, J., Saha, V., Castor, A., Madsen, H. O., Gandemer, V., Cavé, H., Leoni, V., Köhler, R., Ferrari, G. M., Bleckmann, K., Pieters, R., van der Velden, V., Stary, J., Zuna, J., Escherich, G., Stadt, U. zur, Aricò, M., Conter, V., Schrappe, M., Valsecchi, M. G. and Biondi, A. (2017) “Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies”, Haematologica. Pavia, Italy, 103(1), pp. 107-115. doi: 10.3324/haematol.2017.176917.